Mark Lee, MD, PHD
Medical Oncology · Palo Alto
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Lee’s office at (650) 723-7621 to ask if they take your plan before you enroll.
California Medical Board record
Licence A75891 · Current
Licensed to practise in California · since 2001 · expires 2027-04-30 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 27 Part D prescriptions in 2014. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2014 | 27 | None | 0% (0) | None | $7,237 |
| 2013 | 48 | None | None | 29% | $19,862 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 2 (True-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2020 | Their institution | $31,541 |
| Incyte Corporation · An Open Label, Pilot Pharmacokinetic Study of Incb018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis · 2021 | Their institution | $14,757 |
| Incyte Corporation · Topical Ruxolitinib Evaluation in Vitiligo Study 1 (True-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Extension Period in Participants With Vitiligo · 2021 | Their institution | $6,026 |
| Incyte Corporation · A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study To Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo · 2021 | Their institution | $2,486 |
| Incyte Corporation · Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 (True-Che1): A Phase 3, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed By An Open-Label Extension Period in Adults With Chronic Hand Eczema · 2022 | Their institution | $780 |
Professional record
- NPI
- 1881738003
- Licence
- CA A75891California A75891: Current · expires 2027-04-30
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 1 Dna Way # Ms 442b, South San Francisco, CA, 94080
- NPI first listed
- 2007-02-19
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.